tbuckley/cabot-search huggingface dataset:
Herpes zoster infection associated with acute coronary syndrome: a population-based retrospective cohort study
Authors: C.-C. Wang, C.-L. Lin, Y.-J. Chang, G.-J. Wang, F.-C. Sung, C.-H. Kao
Journal: British Journal of Dermatology (2013)

Journal Article Herpes zoster infection associated with acute coronary syndrome: a population‐based retrospective cohort study Get access C.‐C. Wang, C.‐C. Wang Division of Cardiology Department of Internal Medicine Taichung Tzu‐Chi Buddhist General Hospital Taichung TaiwanGraduate Institute of Clinical Medicine Science College of Medicine China Medical University No. 2, Yuh‐Der Road Taichung 404 Taiwan Search for other works by this author on: Oxford Academic Google Scholar C.‐L. Lin, C.‐L. Lin Management Office for Health Data China Medical University Hospital Taichung Taiwan Search for other works by this author on: Oxford Academic Google Scholar Y.‐J. Chang, Y.‐J. Chang Management Office for Health Data China Medical University Hospital Taichung Taiwan Search for other works by this author on: Oxford Academic Google Scholar G.‐J. Wang, G.‐J. Wang Graduate Institute of Clinical Medicine Science College of Medicine China Medical University No. 2, Yuh‐Der Road Taichung 404 Taiwan Search for other works by this author on: Oxford Academic Google Scholar F.‐C. Sung, F.‐C. Sung Management Office for Health Data China Medical University Hospital Taichung TaiwanDepartment of Public Health China Medical University Taichung Taiwan Search for other works by this author on: Oxford Academic Google Scholar C.‐H. Kao C.‐H. Kao Graduate Institute of Clinical Medicine Science College of Medicine China Medical University No. 2, Yuh‐Der Road Taichung 404 TaiwanDepartment of Nuclear Medicine and PET Center China Medical University Hospital Taichung Taiwan Correspondence Chia‐Hung Kao. E‐mail: d10040@mail.cmuh.org.tw Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 170, Issue 5, 1 May 2014, Pages 1122–1129, https://doi.org/10.1111/bjd.12768 Published: 01 May 2014
The Lurking Sperm: Vasectomy Failures
Authors: David N. Barnhouse
Journal: JAMA (1988)

<h3>To the Editor.—</h3> I agree with Dr Schmidt's<sup>1</sup>comments on the technique for vasectomy in that ligation of the vas is far from being any guarantee of its permanent obliteration. I differ, however, in only fulgurating the urethral end of the vas. I then suture the sheath of the vas over the testicular end. Fulguration of the testicular end will lead to the likelihood of blowouts in the epididymis and this will decrease the success of later vasovasostomy. I consequently do not have a problem with there being a sperm granuloma near the site of the ligation, as long as the urethral end is satisfactorily fulgurated.
Assessment of prosthetic heart valve function by Doppler echocardiography. A decade of experience.
Authors: A J Labovitz
Journal: Circulation (1989)

Since the first report of the application of Doppler echocardiography in the evaluation of prosthetic heart valves 10 years ago, dozens of studies have reaffirmed the usefulness of this technique in the noninvasive assessment of transvalvular hemodynamics. Most of these studies have established "normal values" for Doppler-determined pressure gradients and valve areas of prosthetic mitral and aortic valves. Although these studies have established the "normal range," they have all emphasized the individual variability in clinically normal functioning valves. Most of these studies have confirmed the extraordinary sensitivity and specificity of Doppler in detecting prosthetic valve dysfunction. The study by Burstow et al further emphasizes the excellent correlation obtained with simultaneous Doppler and catheter transvalvular pressure gradient measurements. The addition of both color flow Doppler techniques and transesophageal echocardiography can only serve to enhance the clinical diagnostic accuracy of this technique. At the present time, Doppler echocardiography is clearly the procedure of choice for the evaluation of the patient with suspected prosthetic heart valve dysfunction.
The assessment of acne vulgaris—the Leeds technique
Authors: BARBARA M. BURKE, W. J. CUNLIFFE
Journal: British Journal of Dermatology (1984)

We describe two simple, reproducible scoring systems for assessing acne severity, and we emphasize the technical problems which could invalidate either technique. Constant baseline data is desirable for any clinical trial, and our data clearly show that acne patients should ideally be off all treatment for at least 2 months before the start of a therapeutic trial.
Congenital Generalized Lipodystrophy Accompanied by Cystic Angiomatosis
Authors: JOHN D. BRUNZELL
Journal: Annals of Internal Medicine (1968)

Five siblings had congenital generalized lipodystrophy and systemic cystic angiomatosis. Manifestations of each disease and a suggested mechanism of cause related to rapid mobilization of fat stores are discussed. Evidence for autosomal recessive inheritance is presented. Serial studies of the five patients illustrate the progression of these diseases. The simultaneous occurrence of these two diseases suggests that angiomatosis is a common, previously overlooked manifestation of congenital lipodystrophy or a new syndrome in a heterogeneous group of lipodystrophy disorders.
Possible Ocular Adverse Effects Associated With Leuprolide Injections
Authors: F. T. Fraunfelder, R. Edwards
Journal: JAMA (1995)

<h3>To the Editor.</h3> —Leuprolide acetate (Lupron Depo, Lupron Injection, TAP Pharmaceuticals Inc, Deerfield, Ill) is a gonadotropin-releasing hormone used to control endometriosis or advanced prostatic cancer. To our knowledge, this is the first overview of possible adverse ocular events occurring in patients receiving this drug. Cases were received from TAP Pharmaceuticals Inc, the World Health Organization Collaborating Center for International Drug Monitoring, Uppsala, Sweden (which instigated this review), and the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Portland, Ore. The most common adverse ocular event possibly associated with leuprolide acetate is blurred vision, with or without headaches and/or dizziness (Table). This may occur after each injection or as late as the sixth injection, as in one patient. Transitory blurred vision may occur shortly after the injection, usually lasting 1 to 2 hours, but in rare instances may continue for 2 to 3 weeks. This may be a
Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice
Authors: Matthias Friedrich, Petra Deegen, Markus Voelkel, Joachim Wahl, Joachim Schuhmacher, Wolfram Steinke, Dieter Zopf, Robert B. Harris, Patrick A. Baeuerle, Peter Kufer, Benno Rattel
Journal: Cancer Research (2012)

Abstract Blinatumomab, a CD19/CD3-bispecific BiTE antibody has shown high response rates and durable remissions in patients with relapsed or refractory acute lymphocytic leukemia and non-Hodgkin's lymphoma. For treatment of patients with prostate cancer (PCa), we have developed a novel BiTE antibody, MT112/BAY2010112, that is bispecific for prostate-specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex. MT112/BAY 2010112 binds PSMA and CD3 of human and macaque origin allowing for assessment of safety, pharmacodynamics and pharmacokinetics in a relevant animal species. PSMA expressing human PCa cell lines VCaP, 22Rv1, MDA PCa 2b, C4-2, PC3-PSMA and LNCaP were lysed by freshly isolated, unstimulated human T cells redirected by MT112/BAY2010112 at EC50 values ranging between 0.1 and 4 ng/ml (1.8-72 pM). Efficacy of lysis correlated with levels of surface expressed PSMA. No lysis was observed in PSMA-negative PCa cell lines PC3 and DU145, showing the target antigen-specific activity of MT112/BAY2010112. The relevance of cynomolgus monkeys for further nonclinical safety evaluation of MT112/BAY 2010112 was demonstrated by in vitro side-by-side comparison of the BiTE antibody's pharmacological characteristics in human and cynomolgus monkey assay systems. For studying the activity of MT112/BAY 2010112 after subcutaneous (s.c.) administration, human 22Rv1 PCa xenografts were grown s.c. in mice to sizes of &amp;gt;200 mm3 in the absence of human T cells. Three days prior to treatment with BiTE, ex-vivo expanded human T cells were intraperitoneally injected. Animals were treated s.c. at 2.5 mg/kg/d or intravenously (i.v.) at 0.5 mg/kg/d for 28 consecutive days. S.c. administration of MT112/BAY 2010112 resulted in a similar drug exposure, rapid shrinkage and complete remission of established PCa xenografts as seen upon i.v. administration of the BiTE antibody. Treatment with human T cells or vehicle alone had no effect on tumor growth. Compared to i.v. administration, the relative bioavailability of the PSMA BiTE in serum after s.c. injection in mice was approximately 18%. Initial results will be presented showing that 14C-labeled MT112/BAY 2010112 accumulates in s.c. implanted LNCaP PCa tumors of mice after tail vein injection. Based on these preclinical in vivo pharmacology results, treatment of PCa patients with s.c. administered MT112/BAY2010112 appears to be justified. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3526. doi:1538-7445.AM2012-3526
Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia
Authors: D. ROGER ILLINGWORTH
Journal: Annals of Internal Medicine (1984)

Twelve patients with severe heterozygous familial hypercholesterolemia, in whom other hypolipidemic drug therapy had failed to reduce serum cholesterol levels to less than 300 mg/dL, were sequentially treated with mevinolin (a specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis) and colestipol. In ten patients receiving 80 mg/d of mevinolin, plasma cholesterol concentrations decreased 33%, from 487 ± 27 (SE) mg/dL to 326 ± 16 mg/dL. Additional therapy with colestipol resulted in a further 18% decrease, to 269 ± 13 mg/dL. Concentrations of low density lipoprotein (LDL) cholesterol decreased in parallel (54% decrease on combined drug therapy). Plasma concentrations of high density lipoprotein cholesterol did not change significantly, but the LDL:HDL ratio decreased from 8.2 in patients on diet only to 3.8 in patients treated with mevinolin and colestipol. In seven patients treated with 40 mg/d of mevinolin, concentrations of LDL cholesterol decreased by 33%; combined therapy resulted in a further 20% decrease (46% reduction from the level achieved with diet only). No consistent side effects have been noted in up to 24 months of therapy. Combined therapy with mevinolin and colestipol promises to be effective for heterozygous familial hypercholesterolemia.
Application of Continuous Flow Electrophoresis to the Study of the Blood Coagulation Proteins and the Fibrinolytic Enzyme System. I. Normal Human Materials1
Authors: Jessica H. Lewis, Denny Walters, Paul Didisheim, William R. Merchant
Journal: Journal of Clinical Investigation (1958)

Continuous flow filter paper electrophoresis, as developed by Svensson and Brattsen (1), Grassmann and Hannig (2-4) and Durrum (5), offers a method of plasma fractionation in which protein denaturation appears minimal. This study involves the testing of such fractions for biological activity in various coagulation systems. With the exception of fibrinogen, the coagulation proteins are present in plasma in minute amounts which, at the present time, can be assayed only by their activities in specific clotting systems. Many of these coagulation factors are readily denatured; thus, rigid control with particular attention to temperature is necessary to obtain good recovery of biological activity. Previous electrophoretic studies concerning distribution of plasma coagulation proteins have employed paper electrophoresis with elutions from cut strips. Owen and McKenzie (6) found pro
Gary Davidoff, MD, MS
Authors: Samuel H. Kelman
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Healthcare services at Yarl's Wood detention centre are still inadequate, report says
Authors: H. Mooney
Journal: BMJ (2010)

<h3>Introduction</h3> Vasopressin is an alternative vasopressor in the management of septic shock. It spares catecholamine use but whether it improves outcome remains uncertain. Current evidence suggests that it may be most effective if used early and possibly in conjunction with corticosteroids. This trial will compare vasopressin to noradrenaline as initial vasopressor in the management of adult septic shock and investigate whether there is an interaction of vasopressin with corticosteroids. <h3>Methods and analysis</h3> This is a multicentre, factorial (2×2), randomised, double-blind, placebo-controlled trial. 412 patients will be recruited from multiple UK intensive care units and randomised to receive vasopressin (0–0.06 U/min) or noradrenaline (0–12 µg/min) as a continuous intravenous infusion as initial vasopressor therapy. If maximum infusion rates of this first study drug are reached, the patient will be treated with either hydrocortisone (initially 50 mg intravenous bolus six-hourly) or placebo, before additional open-label catecholamine vasopressors are prescribed. The primary outcome of the trial will be the difference in renal failure-free days between treatment groups. Secondary outcomes include need for renal replacement therapy, survival rates, other organ failures and resource utilisation. <h3>Ethics and dissemination</h3> The trial protocol and information sheets have received a favourable opinion from the Oxford A Research Ethics Committee (12/SC/0014). There is an independent Data Monitoring and Ethics Committee and independent membership of the Trial Steering Committee including patient and public involvement. The trial results will be published in peer-reviewed journals and presented at national and international scientific meetings. <h3>Trial registration number:</h3> ISRCTN 20769191 and EudraCT 2011-005363-24.
Trazodone in Essential Tremor
Authors: Nancy A. McLeod
Journal: JAMA (1986)

<h3>To the Editor.—</h3> We have observed significant improvement in response to treatment with trazodone hydrochloride in two patients with marked essential tremor. <h3>Report of Cases.—</h3> Case1.—A 67-year-old man presented with a fiveyear history of progressive action tremor, which had begun to interfere with work, eating, and writing. Due to a prior history of pancreatitis, he had been advised not to drink alcohol. Physical examination findings demonstrated action tremor at a frequency of 8 to 9 Hz but without gait disturbance, nystagmus, or dysequilibrium. A trial of propranolol hydrochloride with a maximum dose of 120 mg/d produced no improvement. A trial of trazodone hydrochloride, 150 mg/d in divided doses, produced improvement in three weeks. The patient reported that he was able to eat without spilling food or drink. Serial handwriting samples documented improvement. A trial without trazodone was marked by deterioration, which reversed with resumption of therapy and persisted over
Overexpression of Dimethylarginine Dimethylaminohydrolase Reduces Tissue Asymmetric Dimethylarginine Levels and Enhances Angiogenesis
Authors: Johannes Jacobi, Karsten Sydow, Georges von Degenfeld, Ying Zhang, Hayan Dayoub, Bingyin Wang, Andrew J. Patterson, Masumi Kimoto, Helen M. Blau, John P. Cooke
Journal: Circulation (2005)

Background— This study was designed to determine whether overexpression of the enzyme dimethylarginine dimethylaminohydrolase (DDAH) could enhance angiogenesis by reducing levels of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). Methods and Results— In DDAH1 transgenic (TG) and wild-type mice (each n=42), the role of DDAH overexpression on angiogenesis was studied by use of the disk angiogenesis system and a murine model of hindlimb ischemia (each n=21). After surgery, animals were treated with either PBS or the NOS inhibitors ADMA or N ω -nitro- l -arginine methyl ester (L-NAME; each 250 μmol · kg −1 · d −1 ) by use of osmotic minipumps (each n=7). L-NAME was chosen to study an inhibitor that is not degraded by DDAH. Neovascularization in the disk angiogenesis system was impaired by both NOS inhibitors; however, TG animals were resistant to the effects of ADMA on neovascularization. Similarly, TG mice were more resistant to the inhibitory effect of ADMA on angioadaptation (angiogenesis and arteriogenesis) after hindlimb ischemia, as assessed by fluorescent microsphere studies and postmortem microangiograms. Enhanced neovascularization and limb perfusion in TG mice were associated with reduced plasma and tissue ADMA levels and enhanced tissue NOS enzyme activity. Conclusions— We describe a novel mechanism by which DDAH regulates postnatal neovascularization. Therapeutic manipulation of DDAH expression or activity may represent a novel approach to restore tissue perfusion.
Analysis of T cell hybridomas. I. Characterization of H-2 and Igh-restricted monoclonal suppressor factors.
Authors: M Minami, K Okuda, S Furusawa, B Benacerraf, M E Dorf
Journal: The Journal of Experimental Medicine (1981)

Five hybridoma T cell lines were prepared by fusion of second order suppressor T cells (Ts2) with the BW5147 thymoma. The culture supernates from these T cell hybrids contained a factor, TsF2, which specifically suppressed 4-hydroxy-3-nitrophenyl acetyl hapten (NP)-induced cutaneous sensitivity responses. TsF2 activity was observed when the factor was administered during the effector phases of the immune response. TsF2 bears I-J determinants and has binding specificity for NPb idiotypic determinants. TsF2 suppressor activity could be absorbed on antigen-primed H-2-incompatible T cells but cannot suppress H-2-incompatible mice. In addition to this H-2 restriction, which maps to the I-J subregion, monoclonal TsF2 also has an Igh genetic restriction. The present results are combined with previous data to describe the cellular interactions leading to immune suppression.
JAUNDICE AND EXFOLIATIVB DEEMATITIS DUE TO PHENYLBUTAZONE
Authors: D. J. MABERLY, R. M. GREENHALGH
Journal: British Journal of Dermatology (1970)

Journal Article JAUNDICE AND EXFOLIATIVB DEEMATITIS DUE TO PHENYLBUTAZONE Get access D. J. MABERLY, D. J. MABERLY Memorial Wing, Watford General Hospital Search for other works by this author on: Oxford Academic Google Scholar R. M. GREENHALGH R. M. GREENHALGH Memorial Wing, Watford General Hospital Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 82, Issue 6, 1 June 1970, Pages 618–619, https://doi.org/10.1111/j.1365-2133.1970.tb06105.x Published: 01 June 1970 Article history Accepted: 30 December 1969 Published: 01 June 1970
A continuing outbreak of isoniazid resistant tuberculosis in North London
Authors: M.C.P. Ruddy, A.P. Davies, M.D. Yates, F.A. Drobniewski, B. Patel, S. Yates, S. Balasegaram, S. Lozewicz, S. Sen, Y. Drabu, G. Duckworth, J. Watson, M. Piper, H. Maguire
Journal: Journal of Infection (2002)
How is representation learned?
Authors: James R. Williamson
Journal: Behavioral and Brain Sciences (1998)

Edelman's memory-based approach to visual representation is preferable to parts-based alternatives. However, the existing algorithms for learning the shape prototypes are biologically implausible because they are nonlocal and nonconstructive. There is an alternative learning algorithm that constructs a mixture model of prototypes on-line, using only local information, and is more biologically plausible and may perform sufficiently well.
Migraine Prevention With β-Blockers: A Placebo Effect?
Authors: Robert J. Gaudet
Journal: JAMA (1985)

<h3>To the Editor.—</h3> β-Blockers are generally regarded as the drugs of choice for the prophylaxis of migraine headaches. This acceptance is based on numerous clinical trials that have shown a greater decrease in headache frequency and severity with β-block ers than with placebo controls.<sup>1</sup>One recent example is the study conducted by Stellar et al,<sup>2</sup>which compared the efficacy of timolol maleate in a 20-week double-blind crossover trial using 107 migraine patients. The study consisted of three phases. The first phase was a four-week baseline period to assess pretreatment headache frequency. Either placebo or timolol was then given to the participants, who had randomly been placed into two groups. After eight weeks the subjects were crossed over to the alternate treatment, and the trial continued for another eight weeks. The results are interesting and bear closer examination. During the first treatment phase there was no difference in the
[383] INTRAHEPATIC INJECTION OF ADENOVIRUS REDUCES INFLAMMATION AND INCREASES GENE TRANSFER AND THERAPEUTIC EFFECT IN MICE
Authors: J. Crettaz, P. Berraondo, I. Mauleon, L. Ochoa, V. Shankar, M. Barajas, N. van Rooijen, S. Kochanek, C. Qian, J. Prieto, R. Hernandez-Alcoceba, G. Gonzalez-Aseguinolaza
Journal: Journal of Hepatology (2007)